Incyte Stock Forecast
NASDAQ: INCYHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
Market open · Delayed 15 min · as of Oct 9, 11:19 AM ET
INCY analyst consensus
Consensus (28 analysts)
buy
Avg. price target
$129.13+14.72%
- Strong buy 2
- Buy 10
- Hold 15
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 28 Wall Street analysts covering Incyte (2026-10-09), 12 rate the stock a buy or strong buy, 15 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $129.13, with a high estimate of $157.00 and a low estimate of $86.00. The average target implies upside of 14.7% from the current price of $112.56.
The spread between the highest and lowest targets is 82.6%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for INCY.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 7% |
| Buy | 10 | 36% |
| Hold | 15 | 54% |
| Sell | 0 | 0% |
| Strong sell | 1 | 4% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $86.00 | -23.60% |
| Average target | $129.13 | +14.72% |
| High target | $157.00 | +39.48% |